Background. Fluoroquinolones are frequently used to replace agents in first-line anti-tuberculosis (anti-TB) regimens in patients with TB who have drug-induced hepatic dysfunction. We investigated the safety of using fluoroquinolone in an area where TB is endemic and where there is a high incidence of drug-induced liver injury.
The rate of DILI associated with anti-TB treatment varied from 5% to 33% in previous studies [1] . The diversity of test subjects and the definitions of hepatotoxicity have made these studies difficult to compare [1] . Possible risk factors have included age, sex, abnormal baseline transaminase levels, malnutrition, and infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus [5] [6] [7] [8] [9] [10] [11] . In Taiwan, the incidence of TB in 2002 was 74.6 cases per 100,000 population, and the incidence has gradually increased since 1980 [12] . The rate of DILI is also high (range, 15%-26%) [6, 13] .
Intervention for DILI due to anti-TB treatment has been suggested when serum transaminase levels are 15 times the upper limit of normal or are 13 times the upper limit of normal in patients with jaundice and/ or symptoms of hepatitis [1, 3] . After liver function normalizes, the resumption of first-line regimens is the standard treatment [1, 3] .
Fluoroquinolones are not recommended as first-line therapies and are reserved for treatment of drug-resistant TB or as a substitute drug for patients who are intolerant to first-line drugs [3, 4] . Levofloxacin and moxifloxacin are newer fluoroquinolones with high bactericidal activity against Mycobacterium tuberculosis [14] [15] [16] [17] . The safety profile of fluoroquinolones, when used as short-course treatment for bacterial infection, has been well established [18, 19] . However, the safety profile of long-term use (duration, 12 weeks) of these agents has not been well studied. Although fluoroquinolones may induce mild elevation of liver function test values, in previous studies, they have not been shown to impose an additional risk of hepatotoxicity in patients with TB [20, 21] . But, the safety of levofloxacin and moxifloxacin in patients with TB and DILI associated with first-line anti-TB treatment is not known. This study was designed to observe the risk factors of DILI and the safety of levofloxacin or moxifloxacin treatment in patients with TB and DILI associated with anti-TB treatment. We anticipated that the use of levofloxacin or moxifloxacin for DILI can avoid single-drug coverage before rechallenge and that these 2 drugs are safe for patients with DILI.
METHODS AND MATERIALS
Study population. From September 2003 through August 2006, patients with active TB who were treated at National Taiwan University Hospital (Taipei) were prospectively enrolled in the study. Active TB was diagnosed (1) if M. tuberculosis was isolated from mycobacterial cultures; (2) if the presence of caseating granulomas, with or without acid-fast bacilli, was determined by histologic examination; or (3) patients improved significantly after completion of a complete course of multidrug anti-TB treatment. In accordance with national policy, patients were followed up by public health nurses, and regular blood samplings were required for liver function monitoring. This study was approved by the institutional review board of National Taiwan University Hospital. Written informed consent was obtained from all patients.
In accordance with the national guidelines for Taiwan [22] , all patients were treated with isoniazid, rifampin, ethambutol, and/or pyrazinamide during the initial phase. Pyrazinamide was withheld if liver function findings were initially abnormal or if chronic liver disease was indicated. All patients initially received regimens with daily dosing at our hospital.
All patients had their liver functions determined before com- mencement of treatment. For patients with known chronic liver disease, regular liver function monitoring-first weekly (for 2 weeks), and then biweekly (for 2 months)-was required. For subjects with seemingly normal liver function, blood samples were obtained monthly. Hepatitis B virus (HBV) carriage was defined as presence of hepatitis B surface antigen (HBsAg). Hepatitis C virus (HCV) carriage was determined on the basis of an enzyme-linked immunosorbent assay positive for HCV antibody. Screening for HIV testing and HBV and HCV carrier status were not routinely offered to patients with TB in our study; they were determined if patients had abnormal liver function test results, had liver or biliary disease, consumed у2 bottles of beer (or an equivalent amount of alcohol) per day, or used hepatotoxic drugs or if they were requested by physicians. Hepatotoxic drugs included ipioglitazone, sulfonylureas, HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors, hydralazine, amiodarone, macrolide, sulfonamides, fluconazole, phenytoin, valproic acid, carbamazepine, tamoxifen, and protease inhibitors. All patients who received a diagnosis of DILI were screened for HBV and HCV carriage. HIV testing was performed if patients agreed.
Patients with active TB were seen monthly, at a minimum, by the responsible physicians. If transaminase levels were 12 times the upper limit of normal, liver function was monitored weekly for 2 weeks and then biweekly thereafter until it returned to normal. If transaminase levels were р2 times the upper limit of normal, liver function tests were repeated at 2 weeks. After transaminases levels decreased, tests were performed only if symptoms recurred. Episodes of hepatitis were considered to be drug induced if transaminase levels were normal before therapy, increased during therapy, and returned to normal after discontinuation of the culprit drugs. Hepatitis was defined as liver transaminase levels 13 times the upper limit of normal in the presence of such symptoms as anorexia, nausea, vomiting, or abdominal pain or as transaminase levels 15 times the upper limit of normal without symptoms. If baseline transaminase levels were high, DILI was defined as an elevated transaminase that occurred during anti-TB therapy that returned to baseline after the halting of medication.
All available patients who received a diagnosis of DILI were treated on the basis of a predefined protocol. All hepatotoxic drugs, including isoniazid, rifampin, and pyrazinamide, were discontinued. Patients were assigned to control or study groups at the physician's discretion. The control group received ethambutol, with or without streptomycin; study groups received either (1) ethambutol plus levofloxacin, with or without streptomycin; or (2) ethambutol plus moxifloxacin, with or without streptomycin. Moxifloxacin was administered at a fixed dosage (400 mg/day), and the levofloxacin dose was based on body weight (500 mg/day for persons who weighed !60 kg and 750 mg/day for those who weighed у60 kg). If the patients still had positive sputum smear results р2 weeks before the diagnosis of DILI, streptomycin was added, unless it was contraindicated or drug resistance was known (figure 1). Once transaminase levels returned to within 1.5 times the upper limit of normal, the original drugs were reintroduced sequentially: isoniazid, rifampin (with or without pyrazinamide), or rifampin plus isoniazid (with or without pyrazinamide).
We collected clinical data, including age, sex, ethnicity, symptoms, comorbidities, medications, alcohol use, method of detection, site of disease, results of acid-fast bacillus smear, culture results, drug susceptibility test results, dose plus duration of all anti-TB drugs prescribed, nutrition, time required for rechallenge, and normalization of liver function.
Statistical analysis. SPSS software for Windows, version 11.0 (SPSS), was used for analysis. Differences between groups were analyzed by independent sample t test or Mann-Whitney U test for continuous variables. Bivariate categorical data were analyzed using the x 2 or Fisher's exact test, as appropriate. If a statistically significant difference ( ) was noted, the var-P ! .05 iables were entered into multivariate analysis using Cox regression to identify factors independently. To ensure the quality of analysis results, the basic model-fitting techniques for (1) variable selection, (2) goodness-of-fit assessment, and (3) regression diagnostics were used in our regression analyses.
RESULTS

Incidence and risk factors of DILI. From September 2003
through August 2006, a total of 1191 patients received a diagnosis of active TB and were treated with anti-TB agents (figure 1) . Pulmonary TB was diagnosed in 894 patients (75.1%); concomitant pulmonary and extrapulmonary TB was found in 48 (4.0%), and sole extrapulmonary disease was diagnosed in 249 patients (20.9%). In our hospital, in vitro fluoroquinolone susceptibility tests were not performed until 2005; only 407 samples were tested in this study. The rate of resistance to fluoroquinolones was 0.7%.
Of 1191 patients, 967 (81.2%) were prescribed rifampin, isoniazid, and pyrazinamide, with or without ethambutol, in the initial phase; the remaining 224 patients (18.8%) received rifampin and isoniazid, with or without ethambutol, in the initial phase. In HIV-positive patients, rifampin was replaced by rifabutin if the patient received combination antiretroviral therapy. In elderly patients, ethambutol was not routinely added. In patients with end-stage renal disease, poorly controlled hyperuricemia, initial abnormal liver function, or chronic liver disease, pyrazinamide was withheld at the discretion of the physician.
After commencement of anti-TB treatment, 134 patients (11.3%) had cases that met the criteria of DILI. Characteristics of patients with or without DILI are presented in table 1. All 134 patients were screened for the presence of HBsAg and HCV antibody, and 110 patients underwent HIV testing.
Of 1057 patients who did not have DILI, 283 patients were screened for the presence of HBsAg and HCV antibody, and 468 patients underwent HIV testing. Forty-six patients were HIV positive. Thirty-eight patients had HBsAg present, and 17 patients had HCV antibody present. Another 21 patients did not undergo HBV or HCV screening but had documented seropositivity for HBsAg noted in prior medical records.
A total of 295 patients had abnormal baseline transaminase levels, and 47 developed hepatitis (6 had HBsAg present, 4 had HCV antibody present, 4 had malignancy, 4 had alcohol consumption as a risk factor, and 3 had positive HIV test results). Of the other 248 patients who did not develop hepatitis, 120 were screened for hepatitis B and C carriage, and 33 had HBsAg present, 12 had HCV antibody present, 42 had malignancy, 18 had alcohol ingestion as a risk factor, and 23 were HIV positive.
Univariate analysis revealed that elevated baseline transaminase levels and receipt of regimens including pyrazinamide were risk factors for DILI. In multivariate analysis, elevated baseline transaminase level was the only factor that predicted DILI (odds ratio, 2.149; 95% confidence interval, 1.364-3.388;
). The intervals between commencement of anti-TB P p .001 therapy and DILI are shown in figure 2 ; 89% of patients developed DILI within 3 months after commencement of treatment. There was no difference in time to development of DILI between patients with versus without abnormal baseline transaminase levels or between those who received regimens with versus without pyrazinamide.
Management of anti-TB DILI with fluoroquinolones. The 134 patients who experienced DILI ceased taking isoniazid, rifampin, and pyrazinamide immediately; 27 (20.1%) received ethambutol, with or without streptomycin, and 52 (38.9%) received ethambutol plus levofloxacin, with or without streptomycin. The other 55 patients (41.0%) received ethambutol plus moxifloxacin, with or without streptomycin. Liver function, including transaminase and bilirubin levels, was assessed weekly.
In the levofloxacin group, only 4 patients experienced adverse reactions to medication; 1 patient had dyspepsia, 1 had dry mouth, 1 had diarrhea, and 1 experienced dizziness. In the moxifloxacin group, 4 patients developed adverse reactions to medication (headache, vomiting, dizziness, and nausea for 1 patient each). Only 2 deaths were reported among the 134 patients; one patient (in the moxifloxacin group) died as a result of progression of cancer, and the other (in the levofloxacin group) died of septic shock due to bacterial infection. There were no deaths stemming from hepatic failure. However, 1 patient in the control group, 1 in the levofloxacin group, and 3 in the moxifloxacin group had persistently abnormal liver function test results. The patients in the control and levofloxacin groups had chronic hepatitis B. One of the 3 patients in the moxifloxacin group had chronic hepatitis C, 1 had chronic hepatitis B, and 1 had no known hepatic disease. Five patients in the control group, 12 in the levofloxacin group, and 10 in the moxifloxacin group refused to comply with regular follow-up visits or rechallenge regimens and were excluded from further analysis. Characteristics of patients who were included in and of patients who were excluded from final analysis are presented in table 2. Patients who were excluded from final analysis had lower rates of pyrazinamide use and longer times to normalization of liver function. Table 3 presents the characteristics of patients who were included in the final analysis. No significant differences, including liver function findings, were found between the groups at the time of DILI diagnosis. There were also no differences in the intervals between the cessation of anti-TB treatment to rechallenge (mean ‫ע‬ standard deviation [SD] for control group, days; for the levofloxacin group, days; 21.9 ‫ע‬ 12.0 19.5 ‫ע‬ 13.7 and for the moxifloxacin group, days) and in the 22.0 ‫ע‬ 11.9 time to normalization of liver function (mean ‫ע‬ SD, 29.1 ‫ע‬ , , and days, respectively). In ad-21.4 25.5 ‫ע‬ 17.6 29.7 ‫ע‬ 14.3 dition, the safety profile of long-term use (duration, 12 weeks) of levofloxacin and moxifloxacin has not been well studied. In the study groups, these 2 drugs were used for a mean duration (‫ע‬SD) of and days, respectively (table 19.5 ‫ע‬ 13.7 22.0 ‫ע‬ 11.9 3), until the patient underwent rechallenge with first-line anti-TB regimens.
After liver function values returned to within 1.5 times the upper limit of normal, the original drugs were reintroduced; the final regimens are shown in table 4. Ninety-six patients were successfully recommenced treatment with at least 2 firstline drugs. Thirteen patients in levofloxacin group and 17 patients in the moxifloxacin group had never discontinued study drugs (table 4) . The last patient in the study completed treatment in April 2007, and all patients underwent at least 20 months of follow-up.
Twenty-seven patients in the 3 study groups were excluded from final analysis because of death (2 patients) and procedural deviations (25 patients). On the basis of the regular follow-up liver function findings, no deaths were reported to be due to hepatic failure.
DISCUSSION
Several factors have been reported as positive predictors of hepatotoxicity during treatment of TB disease [1] . We did not check acetylator status; analysis did not show that age, sex, and alcohol use were risk factors. Some studies have reported that HBV infection was a risk factor for anti-TB drug-induced hepatotoxicity [23, 24] , but this was not found in one prospective study from Taiwan [6] . The controversy may derive from different definitions of DILI and different patient population. In our study, HBsAg, HCV antibody, and HIV tests were not routinely performed until the patient developed hepatitis. Of the patients without DILI, only 283 underwent HBsAg or HCV antibody screening, and 468 underwent HIV testing. We also replaced rifampin with rifabutin in HIV-positive patients when they received combination antiretroviral therapy. In this study, no differences were found in HBV or HCV carriage or in HIV infection between patients with DILI and those without DILI. These results might be biased by the incomplete screening for patients without DILI. Univariate analysis revealed that abnormal baseline transaminase level and regimens that included pyrazinamide were found to be risk factors for DILI. Only abnormal baseline transaminase level remained statistically significant in multivariate analysis. However, as is a common practice for TB treatment, patients with baseline liver disease were often treated with regimens that did not contain pyrazinamide. Given this clear and understandable bias, we could not exclude pyrazinamide as a possible cause of drug-induced liver injury.
Chronic viral hepatitis remained the major etiology for our patients with abnormal baseline transaminase levels: of 167 patients, 55 (10 with and 45 without DILI) were seropositive for HBsAg or HCV antibody. We found that malignancy was also related to abnormal baseline transaminase levels (46 of 295 patients had malignancy). Both disease itself and antineoplastic treatment can contribute to abnormal elevated baseline transaminase levels.
Because of the high incidence of anti-TB drug-induced hepatotoxicity and longer interval to normalization of liver function, new and less hepatotoxic regimens might be necessary before patients undergo rechallenge with first-line anti-TB drugs [1] . Such a regimen may include streptomycin, ethambutol, a fluoroquinolone, or another second-line oral drug. In this study, we found that levofloxacin and moxifloxacin imposed no additional hepatotoxicity on patients with DILI secondary to first-line anti-TB therapy. These 2 drugs could be safely prescribed while waiting for liver function normalization. No cases of DILI occurred among our patients during the follow-up period. Levofloxacin and moxifloxacin were safe for long-term use.
In our study, ethambutol was used alone by control patients, and there is some concern about the development of ethambutol resistance. However, single-drug treatment during rechallenge is allowed for a certain period of time that is not long enough for selection of resistance mutations.
Substitution of moxifloxacin for isoniazid in murine TB does not reduce the efficacy of treatment [25, 26] . Moxifloxacin has been shown to have initial bactericidal activity, comparable with isoniazid [27] . We can reasonably infer that, once moxifloxacin replaces isoniazid for patients with DILI, we can decrease the duration of rechallenge, because it is not necessary to rechallenge with isoniazid. However, the efficacy and cost-effectiveness of moxifloxacin substitution are still to be demonstrated by large, randomized, controlled studies and re-challenges. Thus far, the first-line anti-TB drugs remain the standard treatment.
This study has several limitations. It was not randomized and had a small sample size. We did not analyze the treatment course, because the patient population included some persons with extrapulmonary TB whose treatment mandated longer duration, especially for those with spinal TB and meningeal TB [4, 28] . We did not evaluate relapse as our efficacy measure, because it was not our end point. We used fixed doses of moxifloxacin and 2 different doses of levofloxacin according to body weight. We did not evaluate varied doses of moxifloxacin and levofloxacin.
In conclusion, the incidence of DILI due to first-line anti-TB therapy is high in Taiwan, and abnormal baseline transaminase levels predicted DILI in this study. Levofloxacin dosing by body weight and fixed doses of moxifloxacin caused no additional hepatotoxicity in patients with DILI and can be used in combination with ethambutol during the waiting period for rechallenge with first-line anti-TB drugs. Randomized studies with larger sample sizes are needed to confirm the safety of fluoroquinolones for treatment of DILI.
